Tesamorelin vs Sermorelin vs Ipamorelin (2026)

Tesamorelin is a modified GHRH analog with 44 amino acids and a trans-3-hexenoic acid group at the N-terminus. It is the active ingredient in Egrifta SV, FDA-approved in 2010 for visceral fat reduction in HIV-associated lipodystrophy.

The half-life is 26-38 minutes. Daily subcutaneous injection at 2 mg produces a physiological GH pulse that clears within hours. In Phase III trials, 69% of subjects achieved the FDA responder threshold of greater than 8% visceral adipose tissue reduction (Falutz et al., NEJM, 2007).

Tesamorelin also reduced liver fat and improved triglyceride profiles in the Stanley 2014 JAMA study, making it the most metabolically well-characterized GHRH analog available (Stanley et al., JAMA, 2014). For dosing details, see our tesamorelin dosage for fat loss guide.

Sermorelin is the first 29 amino acids of endogenous GHRH(1-44), representing the shortest fragment that retains full biological activity at the GHRH receptor. It was previously FDA-approved under the brand name Geref for diagnosis and treatment of pediatric growth hormone deficiency.

Geref was discontinued by its manufacturer due to production difficulties, not safety concerns. Sermorelin remains available through compounding pharmacies. Its half-life of 10-20 minutes is the shortest of the three peptides, producing the most transient and natural-feeling GH pulse.

Walker et al. (2006) demonstrated that sermorelin preserves the pituitary neuroendocrine axis and stimulates endogenous hGH mRNA expression, suggesting it supports rather than suppresses the body's own GH production machinery (Walker et al., Horm Res, 2006). Standard dosing is 200-500 mcg subcutaneously before bed. For safety data, see our is sermorelin safe guide.

Ipamorelin is a synthetic pentapeptide (5 amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts on the ghrelin receptor (GHS-R1a), not the GHRH receptor. This makes it mechanistically distinct from both tesamorelin and sermorelin.

The Raun 1998 study established ipamorelin as the first selective GH secretagogue. At doses up to 200 times the effective threshold, cortisol, ACTH, prolactin, FSH, LH, and TSH remained unchanged (Raun et al., Endocrinology, 1998). No other GH-releasing compound has matched this selectivity profile.

The half-life is approximately 2 hours, with a GH peak at about 40 minutes post-injection and dose-proportional pharmacokinetics (Johansen et al., Eur J Clin Pharmacol, 1999). Standard dosing is 100-300 mcg subcutaneously, most commonly paired with CJC-1295 for GHRH-GHRP synergy.

The most important distinction in this three-way comparison is the receptor pathway. Tesamorelin and sermorelin share one pathway. Ipamorelin uses a different one.

Tesamorelin and sermorelin are both GHRH receptor agonists. They bind the GHRH receptor on pituitary somatotroph cells, triggering GH synthesis and release. Because they target the same receptor, stacking them together is pharmacologically redundant.

Ipamorelin targets the ghrelin receptor (GHS-R1a), which triggers GH release through a separate signaling cascade. When you pair a GHRH analog with ipamorelin, you activate two complementary pathways simultaneously. The GHRH analog tells the pituitary to produce GH. Ipamorelin tells the pituitary to release it. The result is a GH pulse larger than either compound achieves alone.

For stacking protocols, see our peptide stacking guide.

The three peptides sit at different rungs of the clinical evidence ladder. This matters for risk assessment and setting realistic expectations.

For visceral fat reduction, tesamorelin has no competition in this group.

Sermorelin and ipamorelin both elevate GH, which promotes lipolysis. Practitioners and users report body composition improvements on both compounds. These reports are consistent with GH physiology but are not the same as measured outcomes from controlled trials.

For targeted fat loss with documented results, tesamorelin is the evidence-based choice. For general body recomposition as part of a broader protocol, all three contribute through GH elevation. See our best peptides for weight loss guide for context.

GH secretion peaks during deep sleep, and all three peptides can enhance this natural rhythm when dosed in the evening.

Sermorelin's 10-20-minute half-life produces a sharp, brief GH pulse that closely resembles the body's own bedtime secretion pattern. Injecting 200-500 mcg of sermorelin before bed amplifies the natural sleep-associated GH surge without prolonged stimulation. Users consistently report deeper sleep and more vivid dreams.

Ipamorelin's 2-hour half-life provides a slightly longer GH pulse, still well within the physiological window. Evening injection before bed is the standard protocol. The GH pulse aligns with early deep sleep stages and clears before morning.

Tesamorelin has no dedicated sleep studies. Its 26-38-minute half-life and daily dosing suggest it could improve sleep through GH-mediated mechanisms, but the data has not been collected.

For natural sleep pattern enhancement, sermorelin is the best match. For targeted GH-mediated sleep improvement, ipamorelin before bed is the standard. For the comparison with MK-677 (which has dedicated sleep data), see our MK-677 vs ipamorelin guide. Also see peptides for sleep.

For long-term anti-aging use, pituitary preservation matters. You want a compound that supports your body's GH machinery rather than overriding it.

Sermorelin scores highest on this criterion. Walker 2006 showed that sermorelin stimulates endogenous hGH mRNA expression, meaning it promotes the pituitary's own GH production capacity (Walker et al., 2006). Its short half-life and natural pulsatile pattern minimize desensitization risk.

Ipamorelin acts on a different receptor entirely, so it does not desensitize the GHRH pathway. Pairing ipamorelin with a GHRH analog like sermorelin or CJC-1295 may actually support pituitary function by providing dual-pathway stimulation without overloading either receptor.

Tesamorelin's potency makes it effective for targeted goals but less ideal for indefinite anti-aging use. Its daily dosing at pharmacological levels (2 mg) represents a stronger stimulus than sermorelin's more moderate approach.

For muscle recovery and body composition in the context of training, the ipamorelin plus CJC-1295 stack is the most widely used protocol.

Ipamorelin's selectivity means no cortisol elevation, which is important for athletes. Cortisol is catabolic; elevated cortisol after training sessions would counteract the anabolic GH signal. GHRP-6 and GHRP-2 both raise cortisol. Ipamorelin does not.

When paired with CJC-1295 (no DAC), the combination delivers GH pulses through two pathways 2-3 times daily, timed around training and sleep. This protocol produces the highest acute GH spikes of any non-HGH approach in practical use.

Tesamorelin's potency makes it effective for recomposition, particularly for reducing stubborn visceral fat in the abdomen. Sermorelin is a gentler option suited for beginners or those prioritizing general recovery over maximum GH output. For training-focused peptide protocols, see our peptides for bodybuilding guide. For CJC-1295 stacking data, see the CJC-1295/ipamorelin benefits guide.

All three peptides are well tolerated at standard doses. The side effect profiles overlap but have distinct differences.

Ipamorelin's zero cortisol and zero prolactin profile at any dose is unique among all GH secretagogues, including sermorelin and tesamorelin. Sermorelin has the mildest overall side effect profile. Tesamorelin has the most comprehensive safety data from Phase III trials.

All three are substantially better tolerated than exogenous HGH, which causes higher rates of water retention, carpal tunnel syndrome, insulin resistance, and joint pain. For ipamorelin-specific side effects, see our CJC-1295/ipamorelin side effects guide. For sermorelin safety, see is sermorelin safe.

Pricing varies by source, formulation, and whether you use brand or compounded products.

Sermorelin is the most budget-friendly option. It does not require stacking with a second compound and has the lowest compounded cost. Ipamorelin becomes more expensive when paired with CJC-1295, which most practitioners consider the standard protocol. Tesamorelin at compounded prices is competitive, but brand Egrifta SV is prohibitive for non-HIV patients without insurance coverage.

This decision matrix consolidates the comparison into actionable guidance.

No single peptide wins every category. The right choice depends on which row matters most to you. For additional GH peptide context, see our CJC-1295 vs sermorelin comparison and the tesamorelin vs CJC-1295 head-to-head.

All three compounds stimulate GH release and elevate IGF-1. Shared precautions apply.

Do not use any GH-stimulating peptide if you have active cancer or a history of hormone-sensitive cancers (prostate, breast, colorectal) without oncologist clearance. Elevated IGF-1 may theoretically promote tumor growth. Monitor IGF-1 levels during use and ensure they stay within the reference range.

Tesamorelin is Category X in pregnancy. It is contraindicated in patients with active malignancy. CJC-1295 and sermorelin share these theoretical concerns without formal contraindication labeling since they lack FDA approval.

Monitor fasting glucose periodically. GH is a counter-regulatory hormone to insulin. Report persistent edema, joint pain that limits function, or headaches that do not resolve with hydration to your prescribing physician. For a detailed safety overview, see our peptide safety guide.